LAEKNA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.21 HKD | -6.97% |
|
+9.08% | -63.77% |
| May. 10 | Laekna Gets Investigational New Drug Approval from Chinese Regulator for Obesity Drug | MT |
| May. 10 | Lekna, Inc. Obtains IND Approval from the CDE for LAE102 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 280K 38.69K 302K | Sales 2023 | 470K 64.94K 507K | Capitalization | 7.06B 975M 7.61B |
|---|---|---|---|---|---|
| Net income 2022 | -782M -108M -843M | Net income 2023 | -369M -50.99M -398M | EV / Sales 2022 * | - |
| Net cash position 2022 | 295M 40.73M 318M | Net cash position 2023 | 723M 99.84M 779M | EV / Sales 2023 | 13,475 x |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
-10.8
x | Employees | 89 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 8.78% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -6.97% | ||
| 1 week | +9.08% | ||
| Current month | +16.67% | ||
| 1 month | +38.92% | ||
| 3 months | +100.84% | ||
| 6 months | -71.84% | ||
| Current year | -63.77% |
1 week
7.15
8.00
1 month
5.168.08
Current year
3.1519.76
1 year
3.1526.45
3 years
3.1526.45
5 years
3.1526.45
10 years
3.1526.45
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 7.21 | -6.97% | 1 804 000 |
| 24-05-20 | 7.75 | +5.30% | 3,537,500 |
| 24-05-17 | 7.36 | -1.08% | 7,087,000 |
| 24-05-16 | 7.44 | -4.62% | 4,887,000 |
| 24-05-14 | 7.8 | +18.00% | 14,572,000 |
Delayed Quote Hong Kong S.E., May 21, 2024 at 04:08 am EDT
More quotes
Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer and liver disease. The Company is mainly engaged in the research and development of drug candidates for monotherapy and combination therapy, focusing on the treatment of various cancers and liver fibrosis diseases. The Company's main product pipelines include LAE002 and LAE001. The LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors. The LAE001 is an androgen synthesis inhibitor that simultaneously inhibits cytochrome P450 family 17 subfamily A member 1 (CYP17A1) and cytochrome P450 family 11 subfamily B member 2 (CYP11B2) for the treatment of prostate cancer. The Company mainly conducts its businesses in China, the United States, Europe and South Korea.
| 1st Jan change | Capi. | |
|---|---|---|
| -63.77% | 388M | |
| +8.33% | 115B | |
| +13.00% | 107B | |
| -13.57% | 22.31B | |
| -3.99% | 21.6B | |
| -5.79% | 18.23B | |
| -39.93% | 17.62B | |
| +7.35% | 14.26B | |
| +33.65% | 12.37B | |
| -27.99% | 8.28B |
- Stock Market
- Equities
- 2105 Stock
